1,240 research outputs found
RESULTS OF A RANDOMIZED, DOUBLE-BLIND STUDY OF ROMIPLOSTIM VERSUS PLACEBO IN PATIENTS WITH LOW OR INT-1 RISK MDS AND THROMBOCYTOPENIA
No full textBACKGROUND:
Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS.
METHODS:
Patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS (N = 250) were randomized 2:1 to receive romiplostim or placebo weekly for 58 weeks.
RESULTS:
The primary endpoint- the number of clinically significant bleeding events (CSBEs) per patient-had a hazard ratio for romiplostim:placebo of 0.83 (95% confidence interval, 0.66-1.05; P = .13). CSBEs were reduced significantly in the romiplostim group for patients who had baseline platelet counts ≥20 × 109 /L (P < .0001). For patients who had baseline platelet counts <20 × 109 /L, there was no difference in the number of CSBEs, but the platelet transfusion rates were higher in the placebo group (P < .0001), which may have affected the overall CSBE results in this group with severe thrombocytopenia. The incidence of bleeding events was reduced significantly in the romiplostim group (relative risk, 0.92), as were protocol-defined platelet transfusions (relative risk, 0.77). Platelet response rates according to 2006 International Working Group criteria were higher for the group that received romiplostim (odds ratio, 15.6). On the basis of interim data, an independent data monitoring committee advised halting study drug because of concerns regarding excess blasts and AML rates with romiplostim (interim hazard ratio, 2.51). At 58 weeks, the AML rates were 6% in the romiplostim group and 4.9% in the placebo group (hazard ratio, 1.20; 95% confidence interval, 0.38-3.84), and the overall survival rates were similar.
CONCLUSIONS:
Romiplostim treatment in patients with low-risk/intermediate-1-risk MDS increased platelet counts and decreased the number of bleeding events and platelet transfusions. Although study drug was discontinued because of an initial concern of AML risk, survival and AML rates were similar with romiplostim and placebo. Cancer 2014. © 2014 Amgen, Inc. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Societ
Recommended from our members
GJ 3929: High-precision Photometric and Doppler Characterization of an Exo-Venus and Its Hot, Mini-Neptune-mass Companion
No full textWe detail the follow-up and characterization of a transiting exo-Venus identified by TESS, GJ 3929b (TOI-2013b), and its nontransiting companion planet, GJ 3929c (TOI-2013c). GJ 3929b is an Earth-sized exoplanet in its star’s Venus zone (P b = 2.616272 ± 0.000005 days; Sb = 17.3 − 0.7 + 0.8 S ⊕) orbiting a nearby M dwarf. GJ 3929c is most likely a nontransiting sub-Neptune. Using the new, ultraprecise NEID spectrometer on the WIYN 3.5 m Telescope at Kitt Peak National Observatory, we are able to modify the mass constraints of planet b reported in previous works and consequently improve the significance of the mass measurement to almost 4σ confidence (M b = 1.75 ± 0.45 M ⊕). We further adjust the orbital period of planet c from its alias at 14.30 ± 0.03 days to the likely true period of 15.04 ± 0.03 days, and we adjust its minimum mass to m sin i = 5.71 ± 0.92 M ⊕. Using the diffuser-assisted ARCTIC imager on the ARC 3.5 m telescope at Apache Point Observatory, in addition to publicly available TESS and LCOGT photometry, we are able to constrain the radius of planet b to R p = 1.09 ± 0.04 R ⊕. GJ 3929b is a top candidate for transmission spectroscopy in its size regime (TSM = 14 ± 4), and future atmospheric studies of GJ 3929b stand to shed light on the nature of small planets orbiting M dwarfs. © 2022. The Author(s). Published by the American Astronomical Society.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]
The Optimization of the Performance Management for Operators in GJ Company Xiamen
No full text本文以绩效管理的基本理论和GJ厦门厂的实际情况为基础，分析了GJ厦门厂一线作业员绩效管理的问题点，并结合公司目前的实际情况提出一线作业员的绩效管理改善方案。该方案以平衡计分卡的绩效管理体系为逻辑，将公司的战略目标分解到制造处，再分解至一线作业员，让作业员的绩效也能从财务面、客户面、内部运营面、学习成长面四个维度上对公司的战略发展起到支撑作用，以促进组织战略目标的实现。 在绩效管理改进方案中，作者特别强调沟通在绩效管理过程中的重要作用，它贯穿了绩效管理的整个过程。沟通有助于促进员工个人绩效的提升和员工个人的成长，从而提升组织的整体效益。 根据GJ厦门厂的实际情况，将一线作业员的绩效考核结...In this paper, operators’ performance management problems in GJ Company are analyzed based on the basic theory of performance management and the real situation of the company. The author propose to break down the company’s strategic targets to lower levels with balanced scorecard system by four levels of financial, customer, internal operation, learning and developing. So that operators’ performa...学位：管理学硕士院系专业：管理学院_工商管理硕士(工商管理硕士)学号：1792012115103
Optimised SEREX technique for the identification of leukaemia associated antigens
No full textThe serological analysis of antigens by recombinant expression cloning (SEREX) has been used by many laboratories to immunoscreen lambda phage cDNA libraries produced from a range of tumour cell types. We and others have found it difficult to extract an optimal quality and quantity of mRNA for the preparation of cDNA libraries which represent the genes transcribed in haematological samples. The difficulty is believed to be due to residual haem groups in the isolated RNA sample which inhibit the activity of reverse transcriptase used in the later production of cDNA. During our preparation of a cDNA library for SEREX studies, we optimised the isolation of mRNA from samples from patients with haematological malignancies. We compared the efficacy of different methods of mRNA extraction using a range of haematological sample sizes and describe the most efficient techniques to maximise mRNA yield and quality for cDNA library production. The phage library we prepared contained a range of cDNA insert sizes, including high molecular weight sequences which, following immunoscreening with autologous patient sera, led to the isolation of 17 novel antigens. Using the methodology described, we have shown SEREX to be effective for the isolation of leukaemia-associated antigens, which may act as targets for immunotherap
Exergy comparison of lunar propellant manufacturing and insertion into LEO using a fully reusable refueling rocket
No full textQuantifying the exergy requirement of propellant insertion into LEO can lead to insight into the feasibility of a lunar propellant-generating architecture. Spacecraft leaving from Earth can greatly reduce their lift-off mass if in-space refueling would possible. Exergy analyses quantify the available energy of a system and show where a reduction in usable energy occurs. Insight into the exergy destruction and input provides a key parameter into the scaling and design of processes and corresponding power systems. The present study aims to define an exergy environment in the lunar PSRs and then to analyze the exergy destruction related to the production of oxygen, ALICE, and hydrolox, in terms of both manufacturing and transportation using a two-stage fully reusable rocket. Extraction processes for ALICE and hydrolox were selected and analyzed w.r.t. the lunar environment to get an understanding of the exergy input. The behavior and exergy requirements of an LEO propellant depot was described. Two fully reusable two-stage rockets using ALICE and hydrolox were designed and compared based on their payload-to-propellant ratio for the oxygen, ALICE, and hydrolox payloads. The study found that the exergetic cost for the insertion of oxygen, hydrolox, and ALICE in LEO were 1.32 GJ/kg , 1.64 GJ/kg, and GJ/kg and 23.3 GJ/kg, 23.4 GJ/kg and 26.9 GJ/kg for the hydrolox and ALICE rocket, respectively.Aerospace Engineerin
Recommended from our members
Double Trouble: Two Transits of the Super-Earth GJ 1132 b Observed with JWST NIRSpec G395H
No full textThe search for rocky planet atmospheres with JWST has focused on planets transiting M dwarfs. Such planets have favorable planet-to-star size ratios, enhancing the amplitude of atmospheric features. Since the expected signal strength of atmospheric features is similar to the single-transit performance of JWST, multiple observations are required to confirm any detection. Here, we present two transit observations of the rocky planet GJ 1132 b with JWST NIRSpec G395H, covering 2.8-5.2 μm. Previous Hubble Space Telescope WFC3 observations of GJ 1132 b were inconclusive, with evidence reported for either an atmosphere or a featureless spectrum based on analyses of the same data set. Our JWST data exhibit substantial differences between the two visits. One transit is consistent with either an H2O-dominated atmosphere containing ∼1% CH4 and trace N2O ( χ ν 2 = 1.13 ) or stellar contamination from unocculted starspots ( χ ν 2 = 1.36 ). However, the second transit is consistent with a featureless spectrum. Neither visit is consistent with a previous report of HCN. Atmospheric variability is unlikely to explain the scale of the observed differences between the visits. Similarly, our out-of-transit stellar spectra show no evidence of changing stellar inhomogeneity between the two visits—observed 8 days apart, only 6.5% of the stellar rotation rate. We further find no evidence of differing instrumental systematic effects between visits. The most plausible explanation is an unlucky random noise draw leading to two significantly discrepant transmission spectra. Our results highlight the importance of multivisit repeatability with JWST prior to claiming atmospheric detections for these small, enigmatic planets. © 2023. The Author(s). Published by the American Astronomical Society.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe.
No full textauthor reply 818-9;
Comment on
High sensitivity of CAP-FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy. [J Allergy Clin Immunol. 2012
Diagnosing Intermittent Faults
No full textIn this working report we outline how to determine the intermittency parameters gj from the activity matrix A (context: DX’08 paper Abreu, Zoeteweij, Van Gemund). We start with the single fault (SF) case and show that averaging over the error vector e is the exact way. We also show that in this way the probability of obtaining exactly this e vector in A is optimal. This is the key insight that allows us to determine g in the general multiple-fault (MF) case. We formulate the gj problem as a (probability) maximization problem, which we solve using a simple gradient ascent technique.Software Computer TechnologyElectrical Engineering, Mathematics and Computer Scienc
- …
